

# Biometrics Unleashed

## Welcome to Health Tech 2.0

### The Era of Health Intelligence

At the dawn of 2025, advancements in Artificial Intelligence (AI), Predictive Analytics (PA), Large Language Models (LLM) and Transformers (GPT) have reset everything to a new normal.

**December, 2025 Shareholder Presentation**



# Forward Looking Statement

This presentation may contain forward-looking statements that involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of AI/ML Innovations Inc., or industry results to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements, which may include but are not limited to, projections regarding future revenues, earnings, strategies, and prospects, are based on numerous assumptions and factors that are inherently uncertain. These assumptions and factors include, but are not limited to, the availability of financing for AI/ML Innovations Inc's projects, changes in commodity prices, changes in demand for and supply of commodities, economic and competitive market conditions, and the regulatory environment. Investors are cautioned not to put undue reliance on forward-looking statements. By their nature, forward-looking statements involve numerous assumptions, inherent risks, and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections, and various future events will not occur. AI/ML Innovations Inc., undertakes no obligation to update publicly or otherwise revise any forward-looking statements, whether as a result of new information, future events, or other such factors that affect this information, except as required by law.

# Enabling Healthier Futures

## AGENDA

- Our **Markets**
  - What We Do & Why it Matters
- Year End **Milestones**
  - People, Products,
  - Technology & IP
  - Regulatory & Quality Management
  - Commercial Traction
- The **Year Ahead**
- Questions & Answers



# Before we Start, some Context

## There is a Global Cardiovascular Disease (CVD) Crisis

- **1.14 billion people** projected to have CVDs by 2050 with **32% of all global deaths** are due to CVDs  
Cite: [World Health Organization](#)
- **Surge in Global CVD Deaths:** Between 1990 and 2021, deaths from cardiovascular diseases increased by approximately 60%, rising from 12.1 million to 20.5 million. Cite: [World Heart Federation](#)
- **High Mortality Rate in the U.S.:** In the United States, cardiovascular disease remains the leading cause of death, with nearly 2,500 individuals succumbing to it daily. Cite: [American Heart Association](#)
- **Projected Increase in CVD Mortality:** Global cardiovascular mortality is projected to increase by 73.4% over the next 25 years, escalating from 20.5 million deaths in 2025 to 35.6 million in 2050. Cite: [Oxford Academic](#)
- **Rising Heart Failure Deaths:** After a period of decline, heart failure-related mortality rates have been increasing. In 2012, the rate was approximately 82 deaths per 100,000 people, which rose to 106 per 100,000 by 2021.  
Cite: [Duke University School of Medicine](#)
- The prevalence of CVDs is projected to increase significantly in the coming decades. Between 2025 and 2050, **a 90% increase in cardiovascular prevalence is anticipated**, with the number of people living with CVDs expected to nearly double from 598 million in 2025 to 1.14 billion in 2050. Cite: [National Library of Medicine](#)

# Before we Start, some Context, continued...

ECGs (Electrocardiograms) play a critical role enabling **early detection, risk assessment, and timely intervention** of Cardiovascular Disease (CVD)

ECGs **reduce mortality, improve outcomes, and empower proactive heart health management**—helping to curb the **global cardiovascular crisis**.


**ECG** is a **non-invasive test** that **records the heart's electrical activity over time to detect abnormalities**.

An ECG helps diagnose:

- **Arrhythmias** (irregular heartbeats)
- **Heart attacks** (detecting damage to heart muscles)
- **Cardiac ischemia** (reduced blood flow to the heart)
- **Electrolyte imbalances** (affecting heart function)

There are **different types of ECG Reports** and **ECG Device Recorders**:

- **Resting ECG** – Performed while the patient is at rest.
- **Stress ECG** – Conducted during exercise to assess heart performance under stress.
- **Holter Monitor ECG** – Continuous 24-48 hour monitoring for ongoing issues.



# What We Do and Why It Matters

We turn raw ECG signals into a powerful, rich, easy-to-analyze data tables.

**We live at the optimal point of leverage — least input, greatest output.**

- Between **Signal Capture** → **Signal Exploit** lives the fulcrum of every ECG workflow — where leverage is highest and why input quality dictates every downstream outcome.
- Our patented and proprietary neural networks perform **waveform-aware segmentation**, pinpointing the **onset and offset of the P-wave**, the **exact QRS duration**, and **T-wave boundaries**
- These are the **fundamental building blocks** of cardiovascular diagnostics, even in noisy environments.

## Why It Matters

- Exploit with a **clean labelled signal**, and everything that follows — classification, triage, and interpretation — becomes faster, clearer, and more reliable
- MaxYield doesn't filter noise away; it understands it. Waveform-Aware, Not Generic Denoise

# What We Do and Why It Matters, continued...

Our Technology lives between Signal Capture and Signal Exploit.

## One Engine – Three Synchronized Outputs

MaxYield generates a unified stream of clinical intelligence, structured in three precise layers:

- **Beat-by-beat label matrix** – for classification and triage logic, capturing every P, QRS, and T morphology
- **Time-series stream** – for beat-level intervals, rhythm trends, and longitudinal analysis.
- **Event & anomaly table** – for detected arrhythmias, signal artifacts, and other irregular events.

Together, they deliver analysis-ready ECG data – **from noise to insight** – in seconds to minutes.

## Three Pathways to Commercialization – One Stack

- **Incumbent Clinical Tools & Wellness Apps:** Strengthening existing diagnostic workflows across OEM platforms and Wellness improving the quality of output for existing Wellness Products.
- **CardioYield™:** The clinical diagnostic and decision-support engine for care environments.
- **Insight360:** The research and wellness platform driving prevention, performance, and longevity analytics.

**MaxYield ECG at the Center** The neural core that powers it all – transforming raw ECG into usable intelligence that fuels clinical precision, research discovery, and human performance.

# Regulated Market Opportunity

## ECG Patch and Holter Monitoring Market Growth

### Projected Market Size

**\$6.4 billion**, and it is projected to grow to approximately **\$11.3 billion by 2032**

### CAGR

6.1%

- Approximately **100 million electrocardiograms (EKGs/ECGs)** are performed annually in the United States
  - Globally, this number is significantly higher, with ~ **300 million** ECGs conducted each year.
- Growth is driven by the rising prevalence of cardiovascular diseases, advancements in ECG technology (such as wireless and wearable devices), and increasing awareness about early detection and preventive healthcare.
- The market includes a range of products, from traditional 12-lead ECG devices to newer technologies like wireless patches and portable monitors.



Highlights & Stats from:  
<https://www.imarcgroup.com/united-states-cardiac-holter-monitor-market>

# Non-Regulated Market Opportunity

## Consumer Wearable Technology (Unregulated Market)

### Projected Market Size

To grow from **\$82.33 billion in 2024** to an astounding **\$230.15 billion** by 2032<sup>1</sup>

CAGR

12.1%



**Key Drivers:** Changing consumer demographics, increased demand for health-focused devices (e.g., smartwatches, fitness trackers), high consumer spending on personal care, and lifestyle products.

- This rapid expansion is fueled by growing interest in personal health tracking, fitness, and lifestyle improvements, driving long-term demand across a variety of sectors.

As of 2024, approximately **400 million wearable devices**<sup>2</sup> are expected to be shipped globally

- This market includes various types of wearables such as smartwatches, fitness trackers, hearables (like wireless earbuds), smart rings, and augmented reality (AR) glasses.
  - Earwear, including products like AirPods, constitutes the largest share of the wearable market, making up over 60% of shipments.
- The market continues to expand, with particular growth in emerging markets, while more affordable brands and mid-tier products are gaining traction due to economic pressures and limited innovation in the premium segments

# Disrupt and Democratize the ECG market

Our Goal to monetize **One Billion ECG files** in the next decade.

We believe with the **Neuralized ECG**, we are redefining the future of cardiac care – soon, monitoring deep heart health data **will be as effortless as checking your pulse**.

We believe that over **100 billion ECGs will be performed globally in the next decade**, driven by AI, wearable technology, and the rising demand for cardiovascular diagnostics projected to exceed \$29 billion by 2031. \*\*

- Cardiovascular disease accounts for **1 in 3 deaths globally**—fueling a global diagnostics market set for rapid expansion.
- **Every second, more than 9 medical ECGs are performed worldwide**, underscoring the growing demand for advanced cardiac diagnostics.\*\*\* **(32,400 per hour)**

\*\* Cardiovascular monitoring and diagnostic devices market will reach approximately \$29.88 billion by 2031, with a CAGR of 5.0% during the forecast period of 2023–2031. Cite: [Conseigic Business Intelligence](#)

\*\*\* Approximately 300 million ECGs are performed worldwide each year. Cite [Nature.com](#)

\*\*\*\* The increase in adoption of Smart Wearables is driving the global smart sensors market size is estimated at USD \$75.58 billion in 2024 and is anticipated to reach around USD \$363.31 billion by 2034, expanding at a CAGR of 17% between 2024 and 2034.Cite: [Precedence Research](#)

# Milestones

## People

- Scale from 5 to 50+

## Products

- MaxYield ECG, Insight 360, CardioYield

## Technology & Intellectual Property

- IP Strategy and Update

## Regulatory & Quality Management

- FDA, Health Canada, Jamaica

## Commercial Traction

- Pipeline, Pilots and Deals



# People Building the best team in the industry

Capital-efficient operating model designed for **scalable growth**

## AIML Team Structure (CY Q4, 2025)

- **54 total people** across the AIML orbit
- Engagement Mix
  - **22 Full-Time** (12 direct, 10 strategic partners)
  - **27 Part-Time / Consultants**
  - **5 Medical Advisors**
- Designed for
  - **Scalable growth without fixed overhead bloat**



# People Building the best team in the industry

## Where the Team Is Deployed

### Product, AI & Engineering — 18

- Neural Cloud, MaxYield™, AI/ML, software & platform scalability

### Clinical Operations & ECG Services — 16

- ECG technicians, labeling, validation, clinical workflows

### Commercial & Revenue Operations — 7

- Sales, marketing, partnerships, go-to-market execution

### Leadership, Board & Medical Advisors — 7

- Strategy, governance, clinical credibility, partnerships

### Regulatory & Quality — 2

- FDA, Health Canada, Quality systems

### Corporate, IR & Professional Services — 4

- Investor relations, governance, recruiting, IP & legal

AIML operates using a combination of **full-time employees, contractors, consultants, and advisors**. Resource allocation reflects management's focus on product development, clinical operations, and commercialization, while maintaining a capital-efficient operating structure.



# Product Suite

## ECG Data Intelligence Platform

A modular software platform designed to process, organize, and present **ECG data** to support **clinical workflows, research, and wellness applications**.

### MaxYield™ ECG

Software engine designed to process ECG signals and extract structured signal features for downstream analysis

### Insight360

Powered by MaxYield™

Visualization and reporting software for ECG data review, trending, and information presentation

### CardioYield

Workflow and productivity software intended to support ECG and Holter data review processes

Certain components may be subject to regulatory clearance depending on intended use. Not all features are available for clinical diagnostic purposes.

# We are by Design **Device Agnostic**


## Market Size & Growth

- **ECG Equipment:** \$8.62B (2023); 7.2% CAGR (2024–2030)\*
- **Ambulatory cardiac monitoring:** \$6.42B (2023); 10.4% CAGR (2023–2030)\*
- **Mobile ECG devices:** \$4.13B (2024); 10.1% CAGR (2025–2032)\*\*
- **Smart wearable ECG monitors:** \$1.98B (2024); 10.33% CAGR (2025–2030)\*



\* **ECG Equipment Market (2024 – 2030):** Size, Share & Trends Analysis Report By Product, By Lead (Single Lead ECG, 3 Lead ECG, 2 Lead ECG, 6 Lead ECG, 12-Lead ECG), By End Use (Hospitals), By Region, And Segment Forecasts. Cite: [Grand View Research](#)

\*\* **Mobile ECG Devices Market** Size, Share & Industry Analysis, By Device Type (Patch, Wearable, and Handheld), By Type (Continuous Monitoring and Intermittent Monitoring), By End User (Hospital & Clinics, Home Healthcare, and Others), and Regional Forecast, 2025–2032  
Cite: [Fortune Business Insights](#)






AI/ML  
INNOVATIONS  
INC.

Introducing  
**MaxYield™**  
Our X-Factor


# MaxYield™

## Maximum Diagnostic Yield


- Our flagship technology – our “X-Factor” – is a **Signal Processing Neural Network** (NN), that expertly isolates and extracts an ECG waveform from all the noise in a signal.
- Our **Signal Intelligence** algorithms are **device agnostic**, capable of identifying and analyzing distinctive traits within any signal data.
- Our Neural Networks **learn hidden structures of any signal** and classify important features to quantify biomarkers and uncover new digital biomarkers.



# MaxYield™ – Maximum Diagnostic Yield




We make **Every Beat Count**: Isolates clean signals from noisy data for **Actionable Information**



We have created a new **Gold Standard**:  
**Beat-by-Beat Analysis & Noise Reduction**

# MaxYield - Immediately Reduce or Eliminate Artifacts



Output CSV file with time-stamped values

ECG_P_Onsets	ECG_P_Offsets	ECG_R_Onsets	ECG_R_Offsets	ECG_T_Onsets	ECG_T_Offsets
1820	1920	2000	2140	2208	2440
2776	2876	2952	3088	3172	3396
3728	3840	3900	4036	4116	4344
4660	4760	4836	4984	5048	5276

*“By instantly filtering out artifacts, we significantly reduce time spent identifying false signals that are often mistaken for true cardiac events.”*

*In many current systems, artifacts are frequently misinterpreted as cardiac events, especially in long-term recordings, where large data volumes slow down accurate reporting.”*


*Dan Pimental, Registered Cardiology Technologist.*


- MaxYield™ and our **patented Advanced Signal Intelligence Algorithm** will **immediately double to triple your ECG review throughput.**
  - As validated by in-house experts, third party Labs and Diagnostics clinics through A/B testing.
  - No need for extensive filtering or additional time spent on cleaning noisy signals

# White Paper

<https://www.theneuralcloud.com/maxyield-white-paper>

- **MaxYield vs. 15 Registered Cardiology Technologists**
  - Our White Paper compared MaxYield's neural network P, QRS, and T Wave detection with experts - ranking second only to the top human expert.
- **Increase Technician Throughput**
  - Traditional Holter reporting methods allow for only 3-5 cases per day per technician, limiting daily output and scaling operations.
  - With the same team using MaxYield, 3-5x this number while maintaining quality & confidence
- **Most Importantly, Lives**
  - **Critical Diagnostic Gaps:** The time inefficiencies and throughput limitations
  - Every missed detail can represent a lost opportunity for intervention, affecting patient outcomes.





AI/ML  
INNOVATIONS  
INC.

# Insight360

# Comprehensive ECG Reporting

### Report Sections

- Header
- Events
- HRV Analysis
- Quality Control
- RR Interval Trend
- ST Segment Trend
- Bradycardia/Tachycardia
- QT/QTc Analysis

### Report Preview

MaxYield Analytics Dashboard

71.5	99.1%	0.9%	100%
Avg HR (bpm)	Normal Beats	Arrhythmias	Quality
22.62	300	2652 ms	
Min HR (bpm)	Max HR (bpm)	Longest RR Interval	2025-10-08 at 10:57:53

### Heart Rate Analysis

Heart Rate Chart Configuration

Time Interval	Heart Rate (bpm)
22:09:53	64
22:54:45	67
23:41:44	49
00:28:02	52
01:14:54	71
02:00:36	80
02:48:36	90
03:30:50	113
04:16:52	100
05:02:10	
05:49:56	
06:33:34	
07:14:57	
07:53:52	
08:27:28	
09:02:18	
09:34:47	
09:58:48	
10:19:49	
10:49:24	
11:08:18	

Our Custom Report Building Tool, **Insight360**

**Insight360**  
Powered by MaxYield™

## Data Presentation

Offers detailed cardiac metrics – *peaks, onsets, offsets, intervals, and amplitudes* – in both CSV and PDF report formats.

## Statistical Analysis

Introduces *advanced statistical analysis for ECG data*, providing unprecedented insights and observations to end users.

## Custom Reporting

Our *no-code, drag-and-drop* user interface allows anyone to easily build, configure & template reports

# Goals of ECG Support Tool

## Faster Analysis Times:

- Reduces analysis time from hours to minutes, optimizing efficiency, particularly in remote settings.

## Improved Diagnostic Accuracy And Yield:

- By providing automated, precise annotations, Neural Cloud aims to deliver better clinical outcomes and more reliable data for healthcare professionals.

*"This has never been done before, except in extremely laborious ways.*

*We can now study PR interval behavior in athletes, in sleep apnea, in exercise - all at scale. Before, this was manual work; now it's automated.*


*When you have baseline wander, the ST segments are not meaningful. What you've done is filtered out the noise from ST segments"*

Dr. Paul Dorian  
Professor of Medicine, University of Toronto  
Division of Cardiology, St Michael's Hospital

### Patient Information

Patient Name:	EDF File:
Patient ID:	File Size: 23.28 MB
Study Name:	Created: 2025-10-10 13:04:44

### MaxYield Analytics Dashboard



### EDF File Information


Recording Information		Technical Information	
Start Date:	07.10.25	EDF Version:	0
Start Time:	22.09.53	Number of Signals:	2
Start DateTime:	2025-10-07 22:09:53	Number of Records:	46944
End DateTime:	2025-10-08 11:12:17	Record Duration:	1.00 seconds
Duration:	13:02:24	Sampling Rate:	-327.00 Hz

### Heart Rate Variability Analysis

Time Domain Metrics			Clinical Assessment	
SDNN	234.58 ms	Overall variability		
RMSD	57.22 ms	Parasympathetic activity		
pNN50	16.51%	Beat variability		
Mean RR	913.30 ms	Average interval		
Overall Risk: Low Autonomic Status: Balanced				

### Data Quality

Valid Beats: 51131 / 51212	99.8%	Good quality	99.8%
----------------------------	-------	--------------	-------



AI/ML  
INNOVATIONS  
INC.

# CardioYield

# CardioYield™

## Holter Reporting Interface for Technicians



### Report Generation


- More Holter reports.
- Same staff. Same devices.

### Increased Throughput

- Faster report prep with technician-led validation.

### Outcome – Net Benefits

- Higher capacity,
- Lower friction,
- Scalable growth.



### Designed by ElectroPhysiologists, Cardiologists and Cardiac Technicians.

- Built on the MaxYield™ engine and refined by in-house technician workflows
- Accelerates report preparation, shifting technician effort from manual screening to focused due diligence

# The Holter Reality in Most Clinics Today

## 3–5 Holter cases per tech per day

- Long review times and manual corrections limit daily output.
- *“Every second, more than 9 medical ECGs are performed worldwide”*

## Backlogs & delayed reports

- Extended turnaround times frustrate both cardiologists and patients.

## Noisy, artifact-heavy tracings

- Muscle tremor, baseline wander, and motion artifacts demand tedious filtering and re-review.

## Tech fatigue & variability

- Hours spent scrolling full disclosure leads to inconsistent reports between technicians.

## Scaling = hiring

- Increased volumes typically require more staff or outsourcing, not better tools.



ECG data volumes are growing, but clinic tools haven't kept pace.

# How CardioYield Improves Holter Workflow



## Today

1. Hours per report
2. Manual event hunting & beat correction
3. Noise-driven false positives
4. Limited cases per technician
5. Inconsistent & Variable report quality

## With CardioYield

1. Reports in minutes, not hours
2. Event-led review: validate, don't hunt
3. Neuralized signals with noise removed upfront
4. 2–3× throughput per technician
5. Standardized, auto-populated reports


## What's Changed?


MaxYield™ plus CardioYield™ handles the signal work so technicians focus on clinical judgment—not scrolling and cleanup.

# How CardioYield Fits the Existing Clinic Workflow



→ **MaxYield™**  
ECG

→  **CardioYield**



## Upload

### “Neuralize” with MaxYield

Holter, Ambulatory,  
or other long-form  
ECGs

Cleans ECG & Quantifies:

- P/QRS/T Wave  
Onsets + Offsets
- Time-series Intervals
- Flags Cardiac Events

## Review & Validate

Technicians use CardioYield

- Review flagged events
- Navigate full disclosure
- Confirm key findings

## Report & Export

Structured report  
fields auto-populate  
and export as a  
clinically ready PDF for  
cardiologist sign-off.



**CardioYield**

# Take The Next Step Getting Started With CardioYield



## No hardware changes required

CardioYield is device-agnostic & works with your current Holter devices

## Simple data integration


We configure import formats for your existing recorders

## Pilot & benchmark

Compare CardioYield vs. your current workflow on a defined set of studies

## Train & go live

Short technician training;  
Start generating reports in days, not months



[Click to watch our in-house Technician walk through the features of CardioYield](#)

# Expert Testimonials



*"Neural Cloud's Holter analysis software is revolutionary. Unlike others limited to basic QRS detection, it accurately measures P waves, QRS complexes, and T waves, allowing for faster, more precise anomaly detection."*

**Dr. Alan Rabinowitz, Cardiologist**

*"The advanced algorithm identifies Atrioventricular blocks at varying degrees, improving accuracy and efficiency significantly in ECG analysis without manual intervention."*

**Dr. Mark Deyell,  
Electrophysiologist**

*"Its superior artifact filtering drastically reduces noise, producing clinically acceptable tracings that enhance the speed and accuracy of Holter analysis."*

**Dr. Brett Heilbron, Cardiologist**

## Increased Case Handling

*"Thanks to its efficiency, Neural Cloud's software can potentially increase our case throughput from 3-5 to 25-30+ cases per day, optimizing our workflow and patient care."*

**Daniel Pimental, Certified ECG Technician**

# One ECG Data Intelligence Platform – Multiple Markets




**Quicker:** Rapid turnaround, **quantified beat-by-beat tabulation** accelerates analysis & clinical decision-making.

**Cheaper:** Scalable cloud-based AI reduces costs by automating ECG interpretation.

**Better:** Advanced de-noising isolates vital data from signal noise, ensuring **Maximum Diagnostic Yield**.

## Key Advantages:

- **Gold standard** measurement: RR intervals from QRS onset, not just from inaccurate R peaks.
- **Accurate** detection of P waves, unlocking new research insights.
- Enables **automatic**, faster diagnosis of Holter ECGs, even with cheaper, noisier devices.



# Technology & IP - Patents & Trademarks

## Securing Technological Innovation

We have been granted a broad patent, with little prior art based upon submissions 12 months ago. **Our latest filings are 10 X in specificity.**

Working with **Wolf Greenfield Sack**, one of the world's best Life Sciences Intellectual Property Law firms:

- We are actively developing a **multi-pronged, multi-year IP Strategy** that includes both **public and proprietary IP** filings. Our goal is to ensure our IP portfolio has the breadth and depth required to ensure our ongoing success.

## Current Focus Areas:

- Rhythm-Based Health Conditions: Patents include novel neural network architectures for analyzing ECG rhythms, offering precise diagnostics of rhythm-related conditions.
- Beat-Based Health Conditions: Covers innovative methods to analyze individual heartbeat components, enhancing diagnostics for beat-specific health anomalies.



# Regulatory Pathway & Quality Framework

## United States (FDA)

- **MaxYield™ — FDA 510(k) pathway**
- **CardioYield™ — FDA 510(k) pathway**

## Canada (Health Canada)

- **MaxYield™ — Class II Medical Device pathway**
- **CardioYield™ — Class II Medical Device pathway**

## Caribbean (Jamaica)

- **CardioYield™ — Regulatory Submission (Jamaica)**

## Quality & Compliance Infrastructure

- **MDSAP / QMS Certification**  
(ISO 13485-aligned quality system supporting U.S., Canada, Jamaica, and international regulatory submissions)



Regulatory pathways are subject to applicable authority review and clearance. Timelines and outcomes cannot be guaranteed.



# Commercial Traction for Q4, CY 2025

**It was a very busy and productive quarter.**

- **September 30th, 2025** AIML and **BC Brain Wellness** Program Launch Pilot to Explore the Heart–Brain Connection
- **October 7th, 2025** AIML Subsidiary NeuralCloud Solutions and **Toronto Heart Centre** Launch a Pilot Program to Test AI-Powered Holter ECG Reporting
- **October 15th, 2025** AIML Subsidiary NeuralCloud Solutions and **Heartdent Center** Ltd. Launch Pilot Project to Advance Cardiac Care in Jamaica
- **October 21st, 2025** AIML Subsidiary NeuralCloud Solutions Commencing Pilot with **Canadian Cardiology Clinic** to Advance AI-Powered ECG Reporting
- **November 4th, 2025** AIML Subsidiary NeuralCloud Solutions Engages Lonacas Consultants to Lead **Regulatory Submission for CardioYield™ in Jamaica**
- **November 11th, 2025** AI/ML Innovations Inc. Announces **Grant of U.S. Patent** Protecting Core ECG Signal-Processing Architecture

# Traction for Q4, CY 2025 continued...

It was a very busy and productive quarter.

- **November 24th, 2025** AIML subsidiary Neural Cloud begins pilot at **The Hospital for Sick Children (SickKids)** to Advance AI-Enabled Pediatric Cardiac Care
  - Pilot Project to Explore AI-Driven ECG Signal Processing and Predictive Deterioration Models in Pediatric Cardiac Care
- **November 26th, 2025** AIML subsidiary NeuralCloud Signs Commercial Term Sheet with **Equimetrics to Deploy MaxYield™ and CardioYield™** across Equine Cardiac Monitoring Platforms
- **December 2nd, 2025** AIML subsidiary NeuralCloud Enters Pilot with **Cornerstone Physiotherapy** to Deploy MaxYield™ and Insight360™ for Elite Athlete Cardiac Performance Testing
- **December 9, 2025** AIML subsidiary NeuralCloud Solutions Signs Commercial Term Sheet with **Culminate H Labs to Deploy MaxYield™ and Insight360™** into INTRINSICA's DNA-Guided Biofeedback Wellness Ecosystem



# The Year Ahead ... Executing Across Five Value Drivers

## 1. Commercial Traction & Revenue

- Convert pilots and term sheets into **recurring commercial contracts**
- Expand clinic footprint in anticipation of regulatory clearances
- License **MaxYield™, CardioYield™, and Insight360™** across clinical, research, and wellness markets

## 2. Regulatory Clearances & Quality Management

- Advance **FDA, Health Canada, and Jamaica** regulatory pathways
- Maintain MDSAP / ISO 13485-aligned quality infrastructure to support global scale
- Position regulatory readiness as a **commercial accelerant**

## 3. Product, Innovation & Platform Expansion

- Continue rapid iteration of **MaxYield™, CardioYield™, and Insight360™**
- Expand platform capabilities to support **1, 3, 6, 12, 18 Lead ECG, PPG, and multi-signal analysis**
- Progress the **Neural Net** strategy for partners and developers

## 4. Strengthening Our People

- Deepen our bench across **engineering, clinical, regulatory, and commercial leadership**
- Expand our **Science & Product Advisory Council**
- Maintain a capital-efficient operating model designed to scale without overhead bloat

## 5. Shareholder Value & Market Awareness

- Increase market awareness of AIML's **technology leadership and regulatory progress**
- Strengthen investor communications, visibility, and engagement
- Align execution milestones with a clear public-market narrative



# Capital Structure

**253.9 Million**

***Shares Outstanding***

**16 Million**

***Options***

**190.7 Million**


***Warrants Outstanding***

**460.6 Million**

***Fully Diluted***

CSE: **AIML**  
OTCQB: **AIMLF**  
FWB: **42FB**





AI/ML  
INNOVATIONS  
INC.

Ask Me  
Anything